XENON XE 133
LOE ApproachingNDAINHALATIONGAS
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xenon XE 133 is an inhaled noble gas radiopharmaceutical approved in 1976 for pulmonary ventilation imaging. It is used as a diagnostic agent to assess lung function and detect ventilation abnormalities in patients with respiratory disease. The drug works by being inhaled as a radioactive gas that distributes throughout the lungs, allowing visualization via imaging.
LOE Approaching
This aging diagnostic product with approaching loss of exclusivity signals a small, stable team focused on maintenance and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Xenon XE 133 offers limited career growth, with zero linked job openings reflecting the product's mature, declining lifecycle stage. This role is best suited for professionals seeking stable, operational-focused work rather than high-impact growth or innovation opportunities.
Brand ManagerField Sales Representative
Worked on XENON XE 133 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.